Perspective Therapeutics, Inc. short interest in 2024
In 2024, Perspective Therapeutics, Inc.'s disclosed short interest ran from 0.69% of shares outstanding on 12 Jan 2024 to 13.22% on 31 Dec 2024, a change of +12.53 percentage points. The year's high was 15.46% on 29 Nov 2024 and its low 0.67% on 29 Feb 2024, averaging 6.90% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.40 days on 31 Oct 2024. Full history: Perspective Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.69% (12 Jan 2024)
- End of year
- 13.22% (31 Dec 2024)
- Change
- +12.53 pp
- High
- 15.46% (29 Nov 2024)
- Low
- 0.67% (29 Feb 2024)
- Average
- 6.90%
- Highest days to cover
- 13.40 (31 Oct 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.69% | 1.00 | |
| 31 Jan 2024 | 0.73% | 1.00 | results (8-K) |
| 15 Feb 2024 | 1.07% | 1.09 | |
| 29 Feb 2024 | 0.67% | 1.33 | |
| 15 Mar 2024 | 0.67% | 1.00 | |
| 28 Mar 2024 | 1.38% | 2.18 | 10-K filed, results (8-K) |
| 15 Apr 2024 | 1.78% | 1.31 | |
| 30 Apr 2024 | 2.32% | 2.84 | |
| 15 May 2024 | 2.60% | 2.44 | 10-Q filed, results (8-K) |
| 31 May 2024 | 3.99% | 3.17 | |
| 14 Jun 2024 | 5.08% | 4.31 | |
| 15 Aug 2024 | 10.31% | 12.13 | results (8-K), 10-Q filed |
| 30 Aug 2024 | 9.53% | 9.06 | |
| 13 Sep 2024 | 10.59% | 8.74 | |
| 30 Sep 2024 | 14.22% | 7.45 | |
| 15 Oct 2024 | 11.69% | 6.69 | |
| 31 Oct 2024 | 11.90% | 13.40 | |
| 15 Nov 2024 | 12.25% | 9.12 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 15.46% | 2.37 | |
| 13 Dec 2024 | 14.67% | 6.86 | |
| 31 Dec 2024 | 13.22% | 6.89 |
See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.